CN110551692B - hFGF9基因修饰型间充质干细胞及其制备方法和用途 - Google Patents
hFGF9基因修饰型间充质干细胞及其制备方法和用途 Download PDFInfo
- Publication number
- CN110551692B CN110551692B CN201910613765.5A CN201910613765A CN110551692B CN 110551692 B CN110551692 B CN 110551692B CN 201910613765 A CN201910613765 A CN 201910613765A CN 110551692 B CN110551692 B CN 110551692B
- Authority
- CN
- China
- Prior art keywords
- hfgf9
- mesenchymal stem
- gene
- stem cells
- alopecia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000002901 mesenchymal stem cell Anatomy 0.000 title claims abstract description 77
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 58
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 201000004384 Alopecia Diseases 0.000 claims abstract description 31
- 231100000360 alopecia Toxicity 0.000 claims abstract description 22
- 230000006870 function Effects 0.000 claims abstract description 11
- 210000004027 cell Anatomy 0.000 claims description 21
- 241000700605 Viruses Species 0.000 claims description 20
- 210000003954 umbilical cord Anatomy 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 13
- 230000014509 gene expression Effects 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 239000013598 vector Substances 0.000 claims description 9
- 239000002245 particle Substances 0.000 claims description 7
- 102100022464 5'-nucleotidase Human genes 0.000 claims description 6
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims description 6
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims description 6
- 238000004806 packaging method and process Methods 0.000 claims description 6
- 238000010353 genetic engineering Methods 0.000 claims description 5
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 4
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 4
- 239000013592 cell lysate Substances 0.000 claims description 4
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 2
- 230000003660 hair regeneration Effects 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 230000006698 induction Effects 0.000 claims 1
- 210000003780 hair follicle Anatomy 0.000 abstract description 17
- 239000004480 active ingredient Substances 0.000 abstract description 5
- 230000008929 regeneration Effects 0.000 abstract description 5
- 238000011069 regeneration method Methods 0.000 abstract description 5
- 210000000130 stem cell Anatomy 0.000 abstract description 4
- 230000004936 stimulating effect Effects 0.000 abstract description 4
- 239000003102 growth factor Substances 0.000 abstract description 2
- 238000011084 recovery Methods 0.000 abstract description 2
- 239000013589 supplement Substances 0.000 abstract description 2
- 230000007365 immunoregulation Effects 0.000 abstract 1
- 210000004209 hair Anatomy 0.000 description 13
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 230000003698 anagen phase Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000012258 culturing Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 230000003676 hair loss Effects 0.000 description 6
- 208000024963 hair loss Diseases 0.000 description 6
- 238000005457 optimization Methods 0.000 description 6
- 230000003778 catagen phase Effects 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 230000003797 telogen phase Effects 0.000 description 5
- 241000701161 unidentified adenovirus Species 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 102100037241 Endoglin Human genes 0.000 description 3
- 101000881679 Homo sapiens Endoglin Proteins 0.000 description 3
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 description 3
- 102100039564 Leukosialin Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108010019160 Pancreatin Proteins 0.000 description 3
- 206010068168 androgenetic alopecia Diseases 0.000 description 3
- 201000002996 androgenic alopecia Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000003325 follicular Effects 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229940055695 pancreatin Drugs 0.000 description 3
- 230000000737 periodic effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 101150112093 FGF9 gene Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 208000004631 alopecia areata Diseases 0.000 description 2
- 239000002458 cell surface marker Substances 0.000 description 2
- 239000006059 cover glass Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000034756 hair follicle development Effects 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 210000003771 C cell Anatomy 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102000013814 Wnt Human genes 0.000 description 1
- 230000004156 Wnt signaling pathway Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000000442 hair follicle cell Anatomy 0.000 description 1
- 230000003661 hair follicle regeneration Effects 0.000 description 1
- 230000003659 hair regrowth Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 201000002818 limb ischemia Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000003658 preventing hair loss Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000002660 stem cell treatment Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910613765.5A CN110551692B (zh) | 2019-07-09 | 2019-07-09 | hFGF9基因修饰型间充质干细胞及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910613765.5A CN110551692B (zh) | 2019-07-09 | 2019-07-09 | hFGF9基因修饰型间充质干细胞及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110551692A CN110551692A (zh) | 2019-12-10 |
CN110551692B true CN110551692B (zh) | 2021-06-25 |
Family
ID=68736476
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910613765.5A Active CN110551692B (zh) | 2019-07-09 | 2019-07-09 | hFGF9基因修饰型间充质干细胞及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110551692B (zh) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010056759A1 (en) * | 2008-11-12 | 2010-05-20 | The Trustees Of The University Of Pennsylvania | Fibroblast growth factor-9 promotes hair follicle regeneration after wounding |
WO2009132457A1 (en) * | 2008-05-02 | 2009-11-05 | University Of Western Ontario | Fgf-9 and its use relating to blood vessels |
CN102174468A (zh) * | 2011-02-24 | 2011-09-07 | 暨南大学 | 诱导人脐带间充质干细胞分化为***细胞的方法与应用 |
CN103585177A (zh) * | 2012-08-13 | 2014-02-19 | 首都医科大学附属北京口腔医院 | 间充质干细胞和基因修饰的间充质干细胞的用途 |
CN103031278A (zh) * | 2012-12-11 | 2013-04-10 | 中国人民解放军第二军医大学 | Jam1基因修饰间充质干细胞的方法及其应用 |
KR101779932B1 (ko) * | 2015-09-15 | 2017-09-21 | 주식회사 스템랩 | 나노그(Nanog)를 도입한 양수 내 태아 유래 중간엽 줄기세포를 이용한 육모 촉진용 조성물의 제조방법 |
CN105769911A (zh) * | 2016-03-23 | 2016-07-20 | 中国人民解放军第二军医大学 | 间充质干细胞诱导斑秃处毛发再生的方法及应用 |
CN106497886A (zh) * | 2016-12-09 | 2017-03-15 | 北京恒峰铭成生物科技有限公司 | 一种毛发再生诱导液及其制备方法和应用 |
-
2019
- 2019-07-09 CN CN201910613765.5A patent/CN110551692B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN110551692A (zh) | 2019-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2432744T3 (es) | Células del tejido adiposo extramedular y sus aplicaciones en la reconstitución del tejido cardiaco | |
CA2338541C (en) | Genetically modified cd34-negative adherently growing stem cells and their use in gene therapy | |
KR101422559B1 (ko) | 지방유래 줄기세포 배양액, 이의 제조방법, 및 이를 포함하는 발모촉진용 조성물 | |
US20220401518A1 (en) | Mesenchymal stem cell expressing hepatocyte growth factor, and use thereof | |
US20220275337A1 (en) | Cellular compositions comprising viral vectors and methods of treatment | |
CN101857854A (zh) | 表达神经营养因子家族相关基因的间充质干细胞及其应用 | |
CN108588026A (zh) | 高表达il10的临床级间充质干细胞的制备方法及其用途 | |
CN108291196A (zh) | 表达ets转录因子的工程化的内皮细胞 | |
EP3714894B1 (en) | Suicide gene therapeutic agent for brain tumors using pluripotent stem cell | |
CN115996735A (zh) | 细胞组合物和治疗方法 | |
CN110551692B (zh) | hFGF9基因修饰型间充质干细胞及其制备方法和用途 | |
WO2014201986A1 (zh) | 建立单克隆间充质干细胞的方法及其应用 | |
Jin et al. | VP22 and cytosine deaminase fusion gene modified tissue-engineered neural stem cells for glioma therapy | |
Razban et al. | Tube formation potential of BMSCs and USSCs in response to HIF-1α overexpression under hypoxia | |
Kim et al. | Stable gene expression by self-complementary adeno-associated viruses in human MSCs | |
JP7144829B2 (ja) | 安全性と抗炎症作用を高めた間葉系幹細胞 | |
CN113855794A (zh) | 一种基于棘突蛋白基因修饰干细胞的新型冠状病毒疫苗 | |
KR102037823B1 (ko) | 줄기세포 응집체를 이용한 혈관 신생 인자의 대량 수득 방법, 및 이의 용도 | |
KR101022349B1 (ko) | 중배엽간세포 혹은 es세포, 또는 불사화한중배엽간세포로부터 신경계세포로의 분화유도 방법 | |
Jin et al. | Use of rats mesenchymal stem cells modified with mHCN2 gene to create biologic pacemakers | |
WO2001048150A1 (fr) | Cellules pouvant se differencier en cellules du muscle cardiaque | |
RU2521225C2 (ru) | Способ стимулирования регенерации спинного мозга с помощью генетически модифицированных клеток крови пуповины человека | |
Estiri et al. | Therapeutic effects of mesenchymal stem cells expressing erythropoietin on cancer-related anemia in mice model | |
CN118147232B (zh) | 一种过表达tps1间充质干细胞的构建方法及其应用 | |
CN118240883B (zh) | 一种炎症调节能力增强型脐带间充质干细胞及其应用、制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230807 Address after: 712000, 10th Floor, E1 (Building 12), West Yungu Phase I, Fengxi New City, Xixian New Area, Qindu District, Xianyang City, Shaanxi Province Patentee after: Shaanxi Zhonghui Biotechnology Co.,Ltd. Address before: No.52, Sanlihe West Street, Xicheng District, Beijing 100032 Patentee before: Lv Guanting Patentee before: Li Ding |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231128 Address after: Room 1006, 10th Floor, Building E1, West Yungu Phase I, Fengxi New City, Xixian New Area, Xi'an City, Shaanxi Province, 712000 Patentee after: Shaanxi Yungu Zhonghui Biopharmaceutical Co.,Ltd. Address before: 712000, 10th Floor, E1 (Building 12), West Yungu Phase I, Fengxi New City, Xixian New Area, Qindu District, Xianyang City, Shaanxi Province Patentee before: Shaanxi Zhonghui Biotechnology Co.,Ltd. |